Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders Growth (5y) (2022 - 2026)
Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders Growth (5y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.47 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.80% |
| Mar 31, 2026 | -15.72% |
| Dec 31, 2025 | -36.33% |
| Sep 30, 2025 | 107.62% |
| Jun 30, 2025 | 2.28% |
| Mar 31, 2025 | 119.90% |
| Sep 30, 2024 | 17.53% |
| Jun 30, 2024 | 57.20% |
| Mar 31, 2024 | 34.60% |
| Dec 31, 2023 | -8.87% |
| Sep 30, 2023 | 8,445.47% |
| Jun 30, 2023 | -1.89% |
| Mar 31, 2023 | 19.98% |
| Dec 31, 2022 | 0.31% |